ZykadiaCyramzaFruzaqlaFruquintinibImfinzidurvalumabramucirumabBrigatinibceritinib
…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…
8articles mentioning drugs
12drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Trastuzumab deruxtecan ×
Trastuzumab deruxtecan
This drug is selected. Its supporting articles are shown below.
Articles mentioning Trastuzumab deruxtecan
8 articles · page 1 of 1Trastuzumab deruxtecantrastuzumab-deruxtecantrastuzumabHER2-low breast cancerHER2-low tumorshuman breast cancermetastatic breast cancerU of North TexasTrastuzumab-based treatments
…g L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med…
disitamab vedotintrastuzumab deruxtecanT-DXdgastric canceranti-HER2 therapy
…ody-drug conjugates, such as trastuzumab deruxtecan (T-DXd) and disitamab vedotin (RC48), has been pivotal in rendering ‘HER-2-low’ gastric cance…
T-DXdTrastuzumab deruxtecanHER2-positive metastatic breast cancermetastatic breast cancerHER2-low metastatic breast cancerHER2-low diseaseunresectable or metastatic breast cancerHER2-low unresectable or metastatic breast cancerHER2-positive unresectable or metastatic breast cancerHER2-positive disease
…Background and Importance Trastuzumab deruxtecan (T-DXd) is an antibody–drug conjugate with proven efficacy in HER2-pos…
BevacizumabTrastuzumab deruxtecanadavosertibmirvetuximab soravtansineovarian cancerHER2-expressing diseasePROCplatinum-based therapyhyperthermic intraperitoneal chemotherapy
…C), platinum rechallenge retains activity in selected patients. Bevacizumab with chemotherapy improves PFS without OS benefit. Novel antibo…
trastuzumab deruxtecanNIH NCIHER2-low breast cancerThe Harvard Ludwig CenterDana-Farber Cancer InstituteSusan G. Komen FoundationHER2-lowBreast CancerHER2-0 tumors
…he emergence of HER2-targeted antibody-drug conjugates, such as trastuzumab deruxtecan (T-DXd), have transformed the therapeutic landscape for patient…
trastuzumab emtansineTrastuzumab deruxtecanT-DXdbreast cancerHealth CanadaAdvarra Institutional Review Board
…2-positive breast cancer who have received prior treatment with trastuzumab emtansine, or at least one prior anti-HER2-based regimen in the metastati…
docetaxelcarboplatinTrastuzumab deruxtecantrastuzumab emtansineribociclibletrozolepaclitaxeltrastuzumabT-DXdpertuzumab+7 more
…erapy will be included and randomised 1:1 to receive either (1) docetaxel (or paclitaxel), carboplatin, trastuzumab (H) and pertuzumab (P…